Is KROS or KTTA more undervalued in 2026?

CirclFi compares Keros Therapeutics, Inc. (KROS) and Pasithea Therapeutics Corp. (KTTA) using 13 institutional-grade valuation models. KROS has a Quality of Company score of 8.6/10 while KTTA scores 4.1/10.

Which is a better buy — KROS or KTTA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KROS and KTTA valuations compare?

KROS at $11.25 and KTTA at $0.72 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KROS vs KTTA Valuation Comparison 2026 — Intrinsic Value Analysis

KROS

Pharmaceutical Preparations

Keros Therapeutics, Inc.

Quality

8.6

out of 10

Value Trap

SAFE

Price

$11.25

Last close

Models

7/13

Active

KTTA

Pharmaceutical Preparations

Pasithea Therapeutics Corp.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$0.72

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	KROS Fair Value	KROS Upside	KTTA Fair Value	KTTA Upside
Bayesian DCF	Intrinsic	—	—	$1.30	+81.5%
Earnings Power Value	Intrinsic	$40.29	+258.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$20.22	+79.7%	$2.30	+222.0%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KROS vs KTTA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KROS vs KTTA — Which Stock Is More Undervalued?

KROS scores higher with a 8.6/10 quality rating vs KTTA's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Keros Therapeutics, Inc. (KROS) and Pasithea Therapeutics Corp. (KTTA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KROS currently trades at $11.25 with a QOC of 8.6/10, while KTTA trades at $0.72 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).